Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ana P. S. Silva, Priscila V. Coelho, Maristella Anazetti & Patricia U. Simioni. (2017) Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. Human Vaccines & Immunotherapeutics 13:4, pages 843-853.
Read now
Read now
Feliciano Barron, Martha de la Torre-Vallejo, Rosa Luz Luna-Palencia, Andres F Cardona & Oscar Arrieta. (2016) The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety 15:11, pages 1563-1572.
Read now
Read now
Mazen Zaarour, Chanudi Weerasinghe, Bassel Nazha, Samer Hassan & Jean-Paul Atallah. (2015) Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer. Expert Review of Anticancer Therapy 15:11, pages 1327-1336.
Read now
Read now
Valerie Nelson, Jacqueline Ziehr, Mark Agulnik & Melissa Johnson. (2013) Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets and Therapy 6, pages 135-143.
Read now
Read now
Timothy A Yap & Sanjay Popat. (2013) The role of afatinib in the management of non-small cell lung carcinoma. Expert Opinion on Drug Metabolism & Toxicology 9:11, pages 1529-1539.
Read now
Read now
Articles from other publishers (27)
Guangwen Liu, Jinling Xue, Yanli Wang, Zhengzhi Liu, Xue Li, Dongmei Qu, Zhengjie Su, Kaibo Xu, Xinyao Qu, Zhaojuan Qu, Linlin Sun, Mingming Cao, Ying Wang, Xuesong Chen, Jing Yu, Lang Liu, Qiaohuan Deng, Yicheng Zhao, Lixiu Zhang & Haimiao Yang. (2022) A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif® in healthy Chinese subjects. Journal of Cancer Research and Clinical Oncology 149:6, pages 2585-2593.
Crossref
Crossref
Alanood S Almurshedi, Mahasen A Radwan, Bushra Al Quadeib, Basmah Aldosari, Iman M Alfagih & Salma S Almarshidy. (2023) Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay. Journal of Chromatographic Science.
Crossref
Crossref
Wei Cao, Jun Ma, Xuan Jiang & Guangyi Gao. (2022) Afatinib Targeted Therapy Affects the Immune Function and Serum Levels of EGFR and Gastrin-Releasing Peptide Precursor (pro-GRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC). Disease Markers 2022, pages 1-5.
Crossref
Crossref
Alanood S. Almurshedi, Mahasen Radwan, Samia Omar, Ayodele A. Alaiya, Mohamed M. Badran, Hanaa Elsaghire, Imran Y. Saleem & Gillian A. Hutcheon. (2018) A novel pH-sensitive liposome to trigger delivery of afatinib to cancer cells: Impact on lung cancer therapy. Journal of Molecular Liquids 259, pages 154-166.
Crossref
Crossref
Victor H.F. Lee. (2018) Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology 14, pages 4-6.
Crossref
Crossref
Umberto Malapelle, Biagio Ricciuti, Sara Baglivo, Francesco Pepe, Pasquale Pisapia, Paola Anastasi, Marco Tazza, Angelo Sidoni, Anna M. Liberati, Guido Bellezza, Rita Chiari & Giulio Metro. 2018. Small Molecules in Oncology. Small Molecules in Oncology
257
276
.
Nora S Sánchez, Gordon B Mills & Kenna R Mills Shaw. (2017) Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics 18:16, pages 1525-1539.
Crossref
Crossref
Yaxiong Zhang, Zhonghan Zhang, Xiaodan Huang, Shiyang Kang, Gang Chen, Manli Wu, Siyu Miao, Yan Huang, Hongyun Zhao & Li Zhang. (2017) Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non–Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. Clinical Lung Cancer 18:5, pages e333-e340.
Crossref
Crossref
Giovanna Mirone, Stefania Perna & Gabriella Marfe. 2016. Resistance to Tyrosine Kinase Inhibitors. Resistance to Tyrosine Kinase Inhibitors
27
107
.
Sávia R.C. Normando, Felipe M. Cruz & Auro del Giglio. (2015) Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. Anti-Cancer Drugs 26:9, pages 995-1003.
Crossref
Crossref
Seyyed Mortaza Haghgoo, Abdolamir Allameh, Esmaeil Mortaz, Johan Garssen, Gert Folkerts, Peter J. Barnes & Ian M. Adcock. (2015) Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer. European Journal of Pharmacology 754, pages 82-91.
Crossref
Crossref
Robert Pirker. (2015) What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. Future Oncology 11:1, pages 153-167.
Crossref
Crossref
Sarah A. Hayes, Amanda L. Hudson, Stephen J. Clarke, Mark P. Molloy & Viive M. Howell. (2014) From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology 27, pages 118-127.
Crossref
Crossref
Wenhua Liang, Xuan Wu, Wenfeng Fang, Yuanyuan Zhao, Yunpeng Yang, Zhihuang Hu, Cong Xue, Jing Zhang, Jianwei Zhang, Yuxiang Ma, Ting Zhou, Yue Yan, Xue Hou, Tao Qin, Xiaoxiao Dinglin, Ying Tian, Peiyu Huang, Yan Huang, Hongyun Zhao & Li Zhang. (2014) Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. PLoS ONE 9:2, pages e85245.
Crossref
Crossref
Gillian M. Keating. (2014) Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer. Drugs 74:2, pages 207-221.
Crossref
Crossref
Massimo Di MaioCesare Gridelli, Francesco Grossi, Silvia Novello & Filippo de Marinis. (2013) Afatinib in advanced non-small-cell lung cancer. Lung Cancer Management 2:6, pages 493-504.
Crossref
Crossref
Rosselle T. Dungo & Gillian M. Keating. (2013) Afatinib: First Global Approval. Drugs 73:13, pages 1503-1515.
Crossref
Crossref
Kyle W. Robinson & Alan B. Sandler. (2013) EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance. Current Oncology Reports 15:4, pages 396-404.
Crossref
Crossref
Fadi S. Farhat & Wissam Houhou. (2013) Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology 5:4, pages 249-270.
Crossref
Crossref
Pascale Tomasini, Laurent Greillier & Fabrice Barlesi. (2012) Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?. Current Respiratory Care Reports 2:1, pages 17-21.
Crossref
Crossref
Michael Boyer, Pasi Antero Jänne, Tony Mok, Kenneth O’Byrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph O’Connell, Stephen Letrent & Vladan Antic. (2013) Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. Clinical Investigation 3:1, pages 29-35.
Crossref
Crossref
Philip T. CagleTimothy Craig Allen. (2012) Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future. Archives of Pathology & Laboratory Medicine 136:12, pages 1482-1491.
Crossref
Crossref
Amartej Merla & Sanjay Goel. (2012) Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review. Chemotherapy Research and Practice 2012, pages 1-11.
Crossref
Crossref
Caicun Zhou. 2012. Lung Cancer Therapy Annual 7. Lung Cancer Therapy Annual 7
75
84
.
Vincent Fallet, Anne-Marie Ruppert, Virginie Poulot, Roger Lacave, Laure Belmont, Martine Antoine, Jacques Cadranel, Marie Wislez & Armelle Lavolé. (2012) Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient. Journal of Thoracic Oncology 7:6, pages 1061-1063.
Crossref
Crossref
Mette K. Nedergaard, Chris J. Hedegaard & Hans S. Poulsen. (2012) Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies. BioDrugs 26:2, pages 83-99.
Crossref
Crossref
M. Pless. (2011) Das fortgeschrittene LungenkarzinomAdvanced lung cancer. Der Pneumologe 9:1, pages 49-54.
Crossref
Crossref